Head of Medical Solutions Fund for Siemens Venture Capital MINNEAPOLIS, Aug. 22 /PRNewswire-FirstCall/ -- vasamed (OTC:OPTL) (BULLETIN BOARD: OPTL) , a leader in non-invasive, hemodynamic assessment technology used to rapidly detect cardiovascular problems, announced today the election of Dr. Andrew Jay to the company's Board of Directors. "We are delighted to welcome Dr. Jay to our board," said Paulita LaPlante, President and CEO of vasamed. "His long experience as a medical technology analyst, his venture capital success and depth of cardiovascular knowledge bring unique skills to our company that are invaluable to our growth and continued development." Dr. Jay established and serves as the Head of the Medical Solutions Fund for Siemens Venture Capital, Inc. He works closely with the multibillion dollar medical division of Siemens, which is a global leader in imaging, healthcare information technology, and oncology where he interacts with private companies and the venture capital community. He serves as a director of funded companies U-Systems, an ultrasound mammography company and Molecular Insight Pharmaceuticals, a company with a portfolio of nuclear imaging including with a lead product in cardiology. He also serves as a Board Observer at MDdatacor, a healthcare data mining company. For the previous eight years, Dr. Jay was active in the investment banking world as a research analyst leading the medical technology efforts at Wachovia Securities and DeutscheBank Alex Brown. He was actively involved in raising over $2 billion in equity capital for companies in the cardiology, orthopedics, vision, imaging, diabetes, neuro and diagnostic arenas. Prior to this, Dr. Jay ran cases at Arthur D. Little, a $1 billion management consulting firm. Dr. Jay received his M.B.A. from Northwestern Kellogg Graduate School of Management, his D.M.D. from University of Pennsylvania School of Dental Medicine and his B.S. from Rensselaer Polytechnic Institute. About vasamed. vasamed designs, licenses, manufactures and distributes products that can be used by your doctor -- right in the office -- to determine if heart and blood vessels are healthy. vasamed's products and technology include SensiLase(TM) Microvascular Assessment System to monitor small blood vessel health, AcQtrac(TM) Impedance Cardiography (ICG) to monitor heart function and Tissue Carbon Dioxide Technologies to monitor tissue wellness. For more information about vasamed technology and services and new products, please call (800) 695.2737 or see the company's web site at http://www.vasamed.com/ . DATASOURCE: vasamed CONTACT: Wes Peterson, CFO of vasamed, +1-952-944-5857 ext. 542 Web site: http://www.vasamed.com/

Copyright